FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 344:61 January 4, 2001 Number 1 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

The review article in this issue by Goldberg et al. and the accompanying editorial by Hale and Zinberg were sent to G.D. Searle, the manufacturer of misoprostol, which offers the following:

To the Editor: The article by Goldberg et al. on misoprostol and pregnancy¹, the accompanying editorial by Hale and Zinberg,² and the events surrounding the approval by the Food and Drug Administration (FDA) of mifepristone for the termination of pregnancy raise important issues. Searle has been invited to clarify its position and actions in this regard. We at Searle share the overriding concern of Hale and Zinberg that . . . [Full Text of this Article]

References

This article has been cited by other articles:

• El-Refaey, H., Rodeck, C. (2003). Post-partum haemorrhage: definitions, medical and surgical management. A time for change. Br Med Bull 67: 205-217 [Abstract] [Full Text]  
• Gebhardt, D O E (2001). Misoprostol in a topsyturvy world. J. Med. Ethics 27: 205-205 [Full Text]